Pharmacogenetics Pharmacokinetics Treatment 
Alta Sciences
DECEMBER 31, 2024
In Issue 7 of The Altascientist , we delve into these factors, the importance of drug interaction studies, and how to limit adverse effects and maximize treatment response. In some cases, these side effects could be life-threatening, such as drops in blood pressure, irregular heartbeats, or organ damage. The Altascientist, Issue 7, pg.
DrugBank
JULY 14, 2025
The complexity of pharmacokinetics and pharmacodynamics, coupled with the variability in patient populations, makes predicting and managing DDI a particularly challenging aspect of drug development. The most clinically significant pharmacokinetic interactions are often those that influence drug metabolism.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ASPET
FEBRUARY 26, 2024
Panobinostat is a potent pan-HDAC inhibitor that has been tested in multiple studies for the treatment of brain tumors. There have been contrasting views surrounding its efficacy for the treatment of tumors in the CNS following systemic administration when examined in different models or species.
ASPET
SEPTEMBER 16, 2024
GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Acknowledging the potential for inter-species differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited.
ASPET
JUNE 10, 2024
Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. The objective of this study was to evaluate the systemic pharmacokinetics and mechanisms that influence the CNS distribution of WSD0628, a novel and potent ATM inhibitor, in the mouse.
Expert insights. Personalized for you.
52 
Let's personalize your content